Lu X, Wu Z, Wang M, Cheng W
Many patients plateau because they remain at a maintenance dose without reaching their individual therapeutic ceiling, or they've been on the same formulation for 6+ months while their body's tolerance shifts
MHRA / GOV.UK marketing authorisations for tirzepatide, semaglutide and liraglutide products
A new clinical analysis suggests that orforglipron, Eli Lillys first GLP-1 weight-loss pill, may become a strong alternative to weekly injections like Wegovy and Mounjaro
For patients seeking weight-loss coverage, providers might recommend alternatives that are FDA-approved for weight management, like Wegovy or Zepbound
Understanding real transformation timelines helps calibrate expectations